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OBJECTIVE—Growth of white adipose tissue takes place in
normal development and in obesity. A pool of adipose progeni-
tors is responsible for the formation of new adipocytes and for
the potential of this tissue to expand in response to chronic
energy overload. However, factors controlling self-renewal of
human adipose progenitors are largely unknown. We investi-
gated the expression proﬁle and the role of activin A in this
process.
RESEARCH DESIGN AND METHODS—Expression of INHBA/
activin A was investigated in three types of human adipose
progenitors. We then analyzed at the molecular level the function
of activin A during human adipogenesis. We ﬁnally investigated
the status of activin A in adipose tissues of lean and obese
subjects and analyzed macrophage-induced regulation of its
expression.
RESULTS—INHBA/activin A is expressed by adipose progeni-
tors from various fat depots, and its expression dramatically
decreases as progenitors differentiate into adipocytes. Activin A
regulates the number of undifferentiated progenitors. Sustained
activation or inhibition of the activin A pathway impairs or
promotes, respectively, adipocyte differentiation via the C/EBP-
LAP and Smad2 pathway in an autocrine/paracrine manner.
Activin A is expressed at higher levels in adipose tissue of obese
patients compared with the expression levels in lean subjects.
Indeed, activin A levels in adipose progenitors are dramatically
increased by factors secreted by macrophages derived from
obese adipose tissue.
CONCLUSIONS—Altogether, our data show that activin A plays
a signiﬁcant role in human adipogenesis. We propose a model in
which macrophages that are located in adipose tissue regulate
adipose progenitor self-renewal through activin A. Diabetes 59:
2513–2521, 2010
G
rowth of white adipose tissue in normal develop-
ment and in obesity is the result of an increase in
size and number of adipocytes. Given that mature
adipocytes do not divide in vivo, regeneration of
adipocytes and the increase in adipocyte number depend on
self-renewal of a pool of adipose progenitors that remains
present during adult life and that can be recruited to form
new fat cells (1,2). Recently, subpopulations of precursor
cells have been characterized in the stromal-vascular fraction
of rodent and human adipose tissues, such as the CD34
/
CD31
 cell population in the human, where they are as-
sumed to self-renew and be responsible for the maintenance
and for the potential of this tissue to expand in response to
chronic energy excess (3–5).
Obesity is associated with new macrophages that are
recruited into adipose tissue and is accompanied by chronic
low-grade inﬂammation in this tissue (6,7). Interestingly, an
increase in the proportion of human adipose progeni-
tors exhibiting proliferative potential is observed in
obese adipose tissue (8). It has recently been reported
that the differentiation potential of human preadipo-
cytes is inversely correlated with obesity, whereas the
pool of precursor cells was positively correlated to BMI
(9,10), suggesting that the obese microenvironment is
capable of inducing proliferation of human preadipo-
cytes while inhibiting their differentiation. Concordantly,
human macrophage medium stimulates proliferation of
human preadipocytes in vitro (11,12). Therefore, immu-
noinﬂammatory cells that accumulate within adipose tis-
sue with obesity might contribute to fat mass enlargement
through paracrine effects on progenitor cells.
Several factors have been identiﬁed as playing a role in
proliferation or differentiation of murine preadipose cell
lines. However, factors controlling self-renewal, i.e., pro-
liferation and differentiation, of human adipose progeni-
tors in vitro and in vivo are largely unknown. Identiﬁcation
of these factors is of fundamental importance and could
ultimately be translated into clinical interventions.
At the nuclear level, CCAAT/enhancer binding protein
(C/EBP) is one of the earliest partners known to play a
critical role in adipocyte differentiation in murine models
(13). C/EBP exists in two isoforms translated from a
single mRNA by using two AUGs within the same reading
frame, the liver-enriched transcriptional activator pro-
tein (LAP) and the liver–enriched transcriptional inhib-
itory protein (LIP) (14). C/EBP-LAP homodimer
promotes adipogenesis by inducing peroxisome prolifera-
tor–activated receptor (PPAR) and C/EBP expression.
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tion domain but exhibits a higher DNA binding afﬁnity than
that of C/EBP-LAP and potently inhibits adipocyte differ-
entiation. Both C/EBP isoforms are expressed during
adipogenesis, and changes in the LAP-to-LIP ratio have
dramatic consequences on differentiation (15,16). Re-
cently, Kru ¨ppel-like factor (KLF)4 has been shown to be
an essential transactivator of C/EBP gene transcription in
murine 3T3-L1 cells (17). Therefore, C/EBP and KLF4
appear to be key early transcription factors promoting
adipogenesis in murine models.
We analyzed the transcriptome of human multipotent
adipose-derived stem (hMADS) cells (supplementary Fig.
S1, available in an online appendix [http://diabetes.
diabetesjournals.org/cgi/content/full/db10-0013/DC1]) to
identify factors that control human adipogenesis, and we
screened for genes that were differentially expressed in
adipocytes compared with their progenitors (18). Among
these, we focused our attention on secreted proteins. One
of these is activin A. Activin A is a member of the
transforming growth factor- superfamily and regulates a
wide variety of cellular events, including regulation of
growth and metastasis of cancer cells, apoptosis, prolifer-
ation, and differentiation of human embryonic stem cells.
Activin A is also a critical mediator of inﬂammation (19).
Activin A is a secreted protein composed of two inhibin A
(INHBA) subunits. It has been reported that activin A
signaling suppresses differentiation of murine 3T3-L1 cells
(20). In humans, activin A has been positioned as a
proﬁbrotic factor in adipose tissue of obese patients (12).
Altogether, these observations suggest that the activin A
pathway could play a role in adipose tissue biology.
However, no information is available about the autocrine/
paracrine function of activin A on proliferation and differ-
entiation of human adipose progenitors or about activin A
regulation.
We show herein that activin A is expressed by human
adipose progenitors ex vivo and in vitro. It is the ﬁrst
demonstration that activin A promotes proliferation of
hMADS cells and that activin A–treated cells failed to
undergo adipocyte differentiation through activation of
Smad2 signaling and downregulation of C/EBP-LAP ex-
pression. Activin A is more highly expressed in adipose
tissues of obese patients than of lean subjects, and we also
found that activin A is upregulated by adipose tissue
macrophage-secreted factors, demonstrating a link be-
tween adipose progenitor self-renewal and macrophages.
Altogether, our data support the following hypotheses: 1)
that activin A is a novel crucial regulator of human adipose
progenitor’s self-renewal and 2) that the expression of
activin A is regulated by the microenvironment existing in
obese patients where macrophages are present. This path-
way could represent a potential target for controlling the
size of the adipose precursor pool in adipose tissue.
RESEARCH DESIGN AND METHODS
Activin A (Preprotech) was prepared as a 100 g/ml stock solution in culture
medium supplemented with 0.5% FCS. SB431542 was purchased from Sigma-
Aldrich. SB203580 was from CalbioChem. Rosiglitazone (BRL4953) was a gift
from Dr. J.F. Dole (GlaxoSMithKline, King of Prussia, PA).
Preparation of cell extracts and Western blot analysis. Cells were rinsed
with PBS and solubilized in stop buffer containing 50 mmol/l Hepes, pH 7.2;
150 mmol/l NaCl; 10 mmol/l EDTA; 10 mmol/l Na4P2O7; 2 mmol/l Na3VO4; and
1% Triton X-100 supplemented with Protease Inhibitor Cocktail (Roche). The
primary antibodies and dilutions used were as follows: mouse anti–activin A
(1/1,000; R&D Systems); C/EBP (C19, 1/200; Santa Cruz); Smad2/3 and
phospho-Smad2 (1/1,000; Cell Signaling); extracellcular signal–related kinase
(ERK)1/2 and phospho-ERK1/2 (1/2,000 and 1/1,000, respectively; Cell Signal-
ing); enolase 1 (ENO1) (1/1,000; Santa Cruz); KLF4 (1/200; Abcam); -tubulin-1
(1/5,000; Sigma Aldrich); and fatty acid–binding protein (FABP)4 (1/1,000),
which was a gift of Dr. D.A. Bernlohr (Department of Biochemistry, Molecular
Biology and Biophysics, University of Minnesota-Twin Cities, Minneapolis,
Minnesota). Secondary horseradish peroxidase–conjugated antibodies were
purchased from Promega.
Obese and lean adipose tissues. In the ﬁrst group, needle biopsies of
subcutaneous white adipose tissue from 12 morbidly obese (age 41.5  3.2
years; BMI 45.8  1.8 kg/m
2) and seven lean (age 43.71  4.51 years; BMI
21.45  0.45 kg/m
2) women of the same ages were collected. In these groups,
we measured gene expression of INHBA. In a second population, subcutane-
ous and visceral white adipose tissue samples from 11 morbidly obese women
who were candidates for bariatric surgery (age 37.7  2.7 years and BMI
49.9  2.6 kg/m
2) were also collected for expression analysis of the genes
described above. Visceral adipose tissue refers to the omental depot. Informed
consent was obtained from all subjects. All clinical investigations were
performed according to the Declaration of Helsinki and approved by the
ethics committees of the Ho ˆtel-Dieu (Paris, France).
siRNA transfection. hMADS cells were transfected with small interfering
RNA (siRNA) duplexes using HiPerfect reagent (Qiagen) either during the
exponential growth cell phase (2.8  10
4 cells/well) to investigate the effects
of cell proliferation or a day before conﬂuence (7  10
4 cells/well) to
investigate effects on differentiation. siRNAs for human Inhba were as follows:
5	 gaaacaguucuuugucagu 3	 and siSmad2, 5	 ucuuuugugcagagccccaa 3	; siRNA
control duplex was from Eurogentec. Cells were transfected with 8 nmol/l
siRNA in medium supplemented with the low concentration of serum de-
scribed composed of 60% Dulbecco’s modiﬁed Eagle’s medium low glucose,
40% MCDB-201, 10 g/ml insulin, 5 g/ml transferrin, 50 ng/ml selenium, 10
9
mol/l dexamethasone, 50 g/ml ascorbic sodium acid, and 2.5 ng/ml ﬁbroblast
growth factor (FGF)2, supplemented with 0.5% FCS.
Generation of hMADS3-EcoRec cells. 293 FT cells (Invitrogen) were
transfected with pLenti6/Ubc-Slc7a1 (Addgene plasmid 17224) along with
packaging mix using lipofectamine 2000 according to the supplier’s instruc-
tions (Invitrogen). Forty-eight hours after transfection, the supernatant was
collected, ﬁltered through a 0.45-mm pore-size ﬁlter, and transferred to dishes
containing proliferating hMADS3 cells for 24 h in the presence of 5 g/ml
polybrene. Cells expressing the mouse receptor for retrovirus were then
selected in the presence of 2.5 g/ml blasticidin. hMADS3-EcoRec cells
displayed a similar proliferation rate and the same capacities to undergo
differentiation into adipocytes and osteoblasts (not shown).
Retroviral infection of hMADS3-EcoRec cells. Ecotropic retrovirus vector
expressing C/EBP-LIP (Addgene plasmid 15714), C/EBP-LAP (Addgene plas-
mid 15712), Klf4 (Addgene plasmid 17219), or green ﬂuorescent protein (GFP)
(kindly provided by Dr. Kitamura, University of Tokyo, Tokyo, Japan) were
produced in PLAT-E cells (Cell Biolabs). Twenty-four hours after transfection,
medium was collected and transferred to hMADS3-EcoRec dishes for 24 h in the
presence of 5 g/ml polybrene. Twenty-four hours after cells reached conﬂuence,
they were induced to undergo differentiation. With GFP used as a reporter, 80% of
hMADS3-EcoRec cells were transduced using this protocol.
RT-PCR analysis. All primer sequences are described in supplemental Table 1.
Real-time PCR assays were run on an ABI Prism 7000 real-time PCR machine
(PerkinElmer Life Sciences) or in a GeneAmp 7500 detection system (Applied
Biosystems, Courtaboeuf, France). Normalization was performed using the
geometric averages of the housekeeping genes G6PDH, POLR2A, and TBP.
Quantiﬁcation was performed using the comparative DCt method.
Cell proliferation assays. Cells were plated onto 12-well plates (2,900
cells/cm
2), and after the appropriate time cells were trypsinized and counted
with a Coulter counter. For each experiment, three wells per condition were
counted.
Statistical analysis. Statistical signiﬁcance was determined by t tests or
ANOVA with post hoc comparisons by Duncan’s multiple-range test. Proba-
bility values 
0.05 were considered statistically signiﬁcant and are indicated
with a single asterisk; 
0.01 is indicated by double asterisks. Nonparametric
tests were used to compare adipose tissue gene expression between lean and
obese subjects (i.e., Wilcoxon test) and to compare subcutaneous versus
visceral adipose tissue in obese subjects (i.e., paired Wilcoxon ranked test).
RESULTS
INHBA/activin A expression is downregulate during
human adipogenesis in vitro and is preferentially
expressed by undifferentiated adipose progenitors in
vivo. According to the results of a transcriptome analysis
that we previously reported (20), we noticed that the
INHBA gene was downregulated during adipogenic differ-
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sions are not limited to one speciﬁc system, we used three
types of human adipose progenitors, i.e., hMADS cells,
primary culture of preadipocytes, and native CD34
/
CD31
 cell populations (see supplementary Fig. S1 for the
isolation procedure), to conﬁrm the expression of INHBA/
activin A during adipogenesis. As shown in Fig. 1A, the
INHBA gene was expressed by undifferentiated hMADS
cells and its level of expression decreased dramatically
early upon induction of adipocyte differentiation. Protein
levels of activin A secreted by undifferentiated and differ-
entiated cells were in agreement with RNA levels (supple-
mentary Fig. S2). Primary preadipocytes that were isolated
from subcutaneous, mesenteric, and omental fat depots of
adult subjects expressed the INHBA gene and also dis-
played a downregulation of this gene expression when
induced to undergo differentiation (Fig. 1B). These data
indicate that activin A is expressed in adipose progeni-
tors from various human fat depots independently of the
age of the donors and is downregulated as progenitors
undergo adipogenesis.
To check that higher INHBA/activin A expression was
indeed correlated with the undifferentiated state of adi-
pose progenitors in vivo, we monitored the INHBA gene
expression in fractioned human adipose tissue. Human
stromal-vascular fraction (SVF) is known to be a hetero-
geneous cell population containing adipose progenitors
and other cell types, which can be isolated based on
expression of cell-surface markers (4). Isolation of differ-
ent cell subpopulations from the SVF and quantitative
RT-PCR revealed that INHBA was expressed at a higher
level in native CD34
/CD31
 adipose progenitors than in
the adipocyte fraction (Fig. 1C). This result did not ex-
clude the possibility that INHBA could also be expressed
by other cell types resident in the SVF (see DISCUSSION).
Altogether, these data show that activin A is expressed by
undifferentiated adipose progenitors and that this expres-
sion is inversely correlated with adipogenic differentiation.
To reveal the potential relevance of this expression proﬁle,
we then investigated the functional role of activin A in
human adipogenesis.
Activin A increases the number of human undifferen-
tiated adipose-derived stem cells via autocrine/para-
crine activation of the Smad2 signaling pathway. As
shown in Fig. 1 and supplementary Fig. S2, activin A was
secreted by undifferentiated cells and its level decreased
dramatically upon induction of adipocyte differentiation,
suggesting its role in regulating the number of undifferen-
tiated hMADS cells. Thus, we analyzed the effect of activin
A addition in serum-reduced culture conditions that were
previously set up to sustain hMADS cell proliferation. As
displayed in Fig. 2A, activin A supplementation enhanced
cell number in proliferating hMADS cell cultures. En-
hancement of adipocyte progenitor proliferation by activin
A did not impact on their subsequent capacity to under-
go adipocyte differentiation; undifferentiated activin A–
treated cells displayed a potential to undergo adipocyte
differentiation similar to that of untreated cells (not shown).
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FIG. 1. Expression of INHBA/activin A by human adipose progenitors and in adipose
tissues. A: Expression of the INHBA gene in undifferentiated (Und.) and 3 and 15 days
after induction of adipocyte differentiation (Diff.) of hMADS2 cells. Expression was
quantiﬁed by real-time PCR, and results are shown by taking as 100 the signal obtained
in undifferentiated cells. Similar results were obtained with hMADS3 cells. B: Expres-
sion of INHBA gene during differentiation of human primary preadipocytes isolated
from different fat depots. Preadipocytes from indicated fat depots of four subjects were
cultured in parallel to conﬂuence, when differentiation-inducing or control media were
added for 30 days. Expression was quantiﬁed by real-time PCR, and results are shown
by taking as 100 the signal obtained in undifferentiated cells from each fat depot. C:
Expression of the INHBA gene in native progenitor cells, deﬁned as CD34
/CD31
 cells,
and mature adipocytes from adult subcutaneous adipose tissue (AT). Expression of
INHBA was quantiﬁed by real-time PCR (n  18 progenitor cells; n  5 mature
adipocytes). Results are shown by taking as 100 the value obtained in the CD34
/CD31

cell population. Values are means  SEM. **P < 0.01.
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activin A–neutralizing antibody, showing the existence of a
basal activin A autocrine/paracrine signaling pathway in-
volved in undifferentiated hMADS cell number. This conclu-
sion was supported by a gene-silencing approach in which
hMADS cells were transfected with Inhba siRNA (supple-
mentary Fig. S3). Smad2 became phosphorylated in hMADS
cells upon activin A treatment (supplementary Fig. S4A),
strongly suggesting that, as in other cell types, Smad2 medi-
ates the biological effects of activin A (21). Therefore, undif-
ferentiated hMADS cells were transfected with siRNA duplex
directed against Smad2 to investigate the role of the activin
A/Smad2 pathway in regulating number of adipose progeni-
tors (see supplementary Fig. S4B for siRNA effect on Smad2
protein levels). Twenty-four hours after transfection, cells
were or were not stimulated with activin A, and cell number
was quantiﬁed 5 days later. Fig. 2B shows that Smad2
silencing decreased cell number and inhibited the effects of
activin A. Collectively, these data show that activin A regu-
lates the number of undifferentiated hMADS cells through
autocrine/paracrine pathways and that this effect employed
Smad2-dependent mechanisms.
Sustained activin A levels inhibit adipose commit-
ment with a C/EBP-LAP–dependant mechanism. As
shown in Fig. 1, activin A is downregulated upon induction
of differentiation. To identify whether activin A downregu-
lation is necessary for commitment toward the adipocyte
lineage, hMADS cells were induced to undergo adipocyte
differentiation in the absence or presence of exogenous
activin A. Chronic exposure of cells to activin A inhibited
formation of lipid-containing cells and lowered the triglyc-
eride-synthesizing glycerol-3-phosphate dehydrogenase
(GPDH) activity in a dose-dependent manner (Fig. 3A and
B). hMADS cells were then treated with 100 ng/ml activin
A for deﬁned time intervals, and adipogenesis was scored
at day 12. As shown in Fig. 3C, exposure of hMADS cells to
activin A for the ﬁrst 3 days of the differentiation process
led to a dramatic inhibition of differentiation. The highest
level of GPDH inhibition was obtained when cells were
exposed to activin A for the ﬁrst 6 days. Expression of
adipogenic genes, such as fabp4, ppar2, and leptin, was
inhibited when cells were exposed to activin A for the ﬁrst
6 days (Fig. 3D). These data indicate that activin A played
a crucial role during the initial stages of the adipocyte
differentiation program.
Expression of most of the adipogenic genes studied was
downregulated in activin A–treated cells compared with
untreated cells (supplementary Fig. S5B). KLF4 protein
was expressed at low levels and was not altered by activin
A treatment (supplementary Fig. S5C), suggesting that
activin A acts either downstream, or independently, of
KLF4. In contrast, C/EBP transcript (kinetics of expres-
sion during hMADS cell differentiation described in Fig.
S6) and C/EBP-LAP/LIP isoform levels were downregu-
lated in response to activin A (Fig. 3E and supplementary
Fig. S6). Therefore, we hypothesized that antiadipogenic
effects of activin A occur through inhibition of C/EBP-
LAP. If this hypothesis is correct, maintenance of C/EBP-
LAP should abolish the inhibitory effect of activin A on
adipogenesis. To test this hypothesis, we generated an
hMADS-EcoRec cell line permissive to infection with
murine retrovirus, and cells were transduced with a retro-
viral vector expressing LAP or LIP isoforms or GFP as
control. We ascertained that overexpression of LAP pro-
moted adipogenesis of hMADS cells and that overexpres-
sion of LIP inhibited this process (supplementary Fig. S7).
Then, we investigated the consequences of this forced
expression on activin A effects. Whereas inhibition of
adipocyte differentiation by activin A was not affected in
GFP- or LIP-hMADS cells, as assessed by GPDH activities
and FABP4 protein levels, activin A–mediated inhibition of
adipogenesis was abolished in LAP-hMADS cells (Fig. 4).
These data are consistent with the hypothesis that the
inhibitory effect of activin A on adipocyte differentiation is
mediated by regulating C/EBP-LAP levels.
Inhibition of activin A/Smad2 pathway promotes hu-
man adipogenesis. We showed that activin A is secreted
by hMADS cells, while these cells expressed receptors for
activin A, ACVR1A, ACVR1B, and ACVR2A (data not
shown). Thus, we postulated the existence of a basal
autocrine/paracrine signaling pathway that is involved in
hMADS cell differentiation. We used complementary ap-
proaches to investigate the role of endogenous activin A.
First, we used activin A antibodies to neutralize secreted
activin A and SB431542, a potent and selective inhibitor of
the ALK5 receptor, which binds activin A. hMADS cells
were maintained in adipogenic medium in the absence or
presence of 1 g/ml anti–activin A antibodies or 5 mol/l
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FIG. 2. Effects of activin A (Act. A) supplementation and of activin A
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(12-well plates). B: Proliferating hMADS3 cells were transfected with
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increased in the presence of anti–activin A antibodies or
SB431542. Enhanced expression of PPAR and of adi-
ponectin mRNAs, two markers of adipocytes, conﬁrmed at
the molecular level that inhibition of the activin receptor-
like kinase (ALK) 5 induced adipogenesis (not shown).
Because ALK5 can also bind transforming growth factor-,
which was expressed by hMADS cells (not shown), we
speciﬁcally blocked the activin A signaling pathway using
siRNA-mediated gene-silencing approaches. GPDH activ-
ity was increased in early differentiated hMADS cells
transfected with Inhba-siRNA or with Smad2-siRNA com-
pared with GPDH activity in cells transfected with a
scrambled siRNA (Fig. 5B). Inhibition of Smad2 dramati-
cally promoted formation of lipid-containing cells and
levels of the adipogenesis-induced FABP4 protein (supple-
mentary Fig. S8). Together, these data demonstrate the
existence of an autocrine/paracrine loop comprising the
activin A/Smad2 pathway that plays a critical negative role
in adipocyte differentiation of hMADS cells.
Activin A expression is inhibited by dexamethasone
and stimulated by factors secreted by adipose tissue–
derived macrophages. We investigated factors regulat-
ing activin A expression in human adipose progenitors.
First, we analyzed the speciﬁc component(s) of the
adipogenic cocktail that might be involved in downregu-
lating INHBA gene expression. To address this, hMADS
cells maintained in serum-free medium supplemented
with transferrin and insulin were exposed to the various
components of the adipogenic induction cocktail either
alone or in combination. As shown in Fig. 6A, T3,
rosiglitazone, and 3-isobutyl-1-methylxanthine (IBMX)
did not alter INHBA gene expression. In contrast, its
expression was selectively downregulated by dexameth-
asone added alone or combined with the other compo-
nents. Levels of activin A secreted by dexamethasone-
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observed at RNA levels (Fig. 6B). We also wanted to
evaluate whether the expression of the INHBA gene
could be regulated by the in vivo microenvironment of
adipose progenitors. In this context, we compared the
INHBA gene expression levels in subcutaneous fat
depots of lean and obese individuals. Clinical and
biological parameters measured in lean and obese
women are shown in Tables S3 and S4.
As shown in Fig. 7A, RNA levels of INHBA were
signiﬁcantly increased in subcutaneous adipose tissue
of obese subjects compared with lean subjects. Activin
A secretion was also investigated in paired subcutane-
ous and visceral adipose tissue explants from obese
subjects. Activin A was similarly secreted by subcuta-
neous and visceral obese adipose tissue explants (not
shown). Expression of activin receptors type 1 recep-
tors ACVR1A and ACVR1B and type 2 receptors
ACVR2A and ACVR2B has been investigated by RT-PCR.
We observed that gene expression of type 1 (ACVR1B)
and type 2 (ACVR2A and ACVR2B) activin receptors was
not statistically different in adipose tissue of lean and
obese subjects (not shown).
To identify the microenvironment components that
might stimulate activin A expression in obese subjects, we
tested the potential interaction between macrophages and
adipose progenitors. For that purpose, preadipocytes iso-
lated from lean adipose tissue were stimulated with fac-
tors secreted by macrophages selected from the stromal
fraction of obese subcutaneous adipose tissue (adipose
tissue microphages [ATMs]). As shown in Fig. 7B, RNA
levels of INHBA were signiﬁcantly increased in human
preadipocytes that were maintained for 10 days in media
conditioned by ATMs compared with the control condi-
tion. As we reported previously, we observed an increase
in preadipocyte number compared with the control condi-
tion (11). RNA levels of INHBA were also increased when
native CD34
/CD31
 human adipose progenitors were
treated for 24 h with ATM-secreted factors (Fig. 7C).
Finally, we investigated levels of activin A secreted by
undifferentiated hMADS cells after a 24-h stimulation with
ATM-conditioned medium. As shown in Fig. 7D, factors
secreted by ATMs selected from three different biopsies
dramatically increased levels of activin A secreted by
hMADS cells. No activin A was detected in ATM-condi-
tioned media, excluding macrophages as the source of
activin A. Levels of activin A secreted by ATM-conditioned
media–treated cells were in agreement with the increase
observed at the INHBA RNA levels (supplementary Fig.
S9). Altogether, these data show that human macrophage–
secreted factors induce an upregulation of activin A in
human adipose progenitors.
DISCUSSION
The identiﬁcation of factors regulating self-renewal of
adipose progenitor cells could provide a means for better
understanding the mechanisms that lead to hyperplasia
and excessive development of adipose tissue. To our
knowledge, only FGF1 (22) and FGF2, as we have shown
previously (23), were shown to stimulate proliferation of
human adipose progenitors and subsequently to increase
their capacity to undergo differentiation. However, the
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growth remains to be investigated. It has been proposed
recently that the bone morphogenetic protein pathway,
which shares signaling components with the activin path-
way, regulates both adipose cell fate determination and
differentiation of committed preadipocytes as well as
function of mature adipocytes in mouse models (24). The
present study speciﬁes the function of activin A in this
context and proposes that macrophages are niche compo-
nents that are, at least in part, responsible for the activa-
tion of the activin A pathway in human adipocyte
progenitors. INHBB subunits are expressed in mouse and
human adipose tissues, suggesting that activin B and/or
activin AB could also play a role in adipogenesis (25,26). In
contrast to what we show for INHBA, INHBB is preferen-
tially expressed in mature adipocytes, strongly suggesting
that activin B/AB are not involved in early steps of
adipocyte differentiation. Indeed, the authors propose
that INHBB may play an autocrine/paracrine role in
energy balance or the insulin insensitivity associated
with obesity (25–27). Altogether, these data support the
hypothesis that activins are regulators of the different
steps of adipogenesis.
Homozygous inhba mutant mice display a neonatal lethal-
ity phenotype (28). This precludes the study of the role
of activin A during the development of white adipose
tissue.
The Smad2 pathway mediates proliferative and antiadipo-
genic effects of activin A on hMADS cells. Even if other
pathways in activin A–regulated self-renewal might be in-
volved, the Smad2 pathway is likely to play a major role.
Indeed, we observed a weak activation of ERK1/2 upon
addition of activin A and that inhibition of p38 MAPK
had no effect on activin A–induced cell proliferation
(not shown).
Obese adipose tissue is characterized by accumula-
tion of macrophages (6,7), and we show that human
macrophage–secreted factors strongly induce an up-
regulation of activin A in human adipose progenitors
(demonstrated here and previously [12]). Given that we
report here that activin A promotes proliferation and
inhibits adipocyte differentiation of adipose progeni-
tors, it is tempting to propose that the pool of adipose
progenitors increases in adipose tissue of obese patients
compared with that of lean subjects, where macro-
phages are barely present. In agreement with this, we
recently reported an increase of proliferative markers in
the CD34
/CD31
 cell population of obese adipose
tissue (8). Moreover, adipose tissue macrophages have
been shown to inhibit adipogenesis of the CD34
/CD31

cells (29). Altogether, these data support a model of
self-renewal of adipose progenitors regulated by the
obese microenvironment, where activin A plays a criti-
cal role. ATM-secreted factors involved in stimulation of
activin A expression remain to be identiﬁed. Interleu-
kin-1 and/or tumor necrosis factor- are potent candi-
dates; previous studies have shown in another cell
model that activin A secretion is increased upon treat-
ment with these two cytokines (30). The disappearance
of macrophages (31) and reducing activin A levels in
adipose tissue, for instance as a consequence of dieting,
might be favorable to the formation of additional adipo-
cytes from adipose progenitors upon ending dietary
restriction—a situation reminiscent of the “yoyo” phe-
nomenon. Activin A is also a critical mediator of inﬂam-
mation (rev. in [19]). It is interesting to note that
dexamethasone, an anti-inﬂammatory molecule, regu-
lates activin A levels (Fig. 6). In addition to its
stimulating effect on expression of proinﬂammatory
cytokines in macrophages, activin A could promote
ﬁbrosis in adipose tissue (12). Therefore, activin A
signaling could be a target for therapeutic interventions.
At the extracellular level, follistatin can bind to activin
A with high afﬁnity and antagonizes binding to the
activin A receptor. Recently, follistatin has been shown
to reduce inﬂammatory disease severity in mouse ani-
mal models (32). More recently, it has been shown that
recombinant follistatin treatment promotes adipogenic
differentiation of progenitor cells in vitro (33). Activin A
and follistatin can be synthesized by several cell types in
the body. Based on expression of INHBA, preliminary
experiments suggest that activin A is more expressed in
adipose tissue than in muscle and less expressed in
adipose tissue than in liver. We observed that Inhba is
highly expressed in the CD34
/CD14
 cell population
isolated from adipose tissue. Activin A might also be
expressed by macrophages resident in adipose tissue
(not shown). It is interesting to note that activin A was
not detected in adipose tissue macrophage–conditioned
media excluding macrophages as an abundant source of
secreted activin A, whereas adipocyte progenitors se-
crete high levels of activin A in the presence of macro-
phage factors (see Fig. 7). Expression of activin A and of
follistatin in different cell types has to be taken into
Inhba 
β β-actin 
1  2  3  4  5  6  7  A 
B 
-      +  -       +  DEX 
d3 d6 
Activin A 
ENO1 
FIG. 6. Effects of dexamethasone (DEX) on the expression of
INHBA/activin A in human adipose progenitors. A: Individual com-
ponents of the adipogenic cocktail were added to conﬂuent hMADS3
cells alone or in combination. Cells were harvested 3 days later for
semiquantitative PCR analysis. 1, insulin (5 g/ml) and 10 g/ml
transferrin; 2, insulin (5 g/ml) and 10 g/ml transferrin plus 1
mol/l rosiglitazone; 3, insulin (5 g/ml) and 10 g/ml transferrin
plus 0.2 nmol/l triiodothyronine; 4, insulin (5 g/ml) and 10 g/ml
transferrin plus 1 mol/l dexamethasone; 5, insulin (5 g/ml) and 10
g/ml transferrin plus 100 mol/l isobutyl-methylxanthine; 6, insu-
lin (5 g/ml) and 10 g/ml transferrin plus 1 mol/l rosiglitazone,
0.2 nmol/l triiodothyronine, 100 mol/l isobutyl-methylxanthine,
and 1 mol/l dexamethasone; 7, insulin (5 g/ml) and 10 g/ml
transferrin plus 1 mol/l rosiglitazone, 0.2 nmol/l triiodothyronine,
and 100 mol/l isobutyl-methylxanthine. B: Inhibition of activin A
secretion by dexamethasone. hMADS3 cells were maintained in 5
g/ml insulin and 10 g/ml transferrin medium in the absence or
presence of 1 mol/l dexamethasone. Culture media were collected
3 or 6 days later, ﬁltered on 0.2-m membranes, and concentrated
with Amicon ultra-15 columns (NMWL, three KDa; Millipore). Levels
of activin A were analyzed by Western blot performed under nonre-
ducing conditions because anti–activin A antibody selectively binds
to the dimeric form of activin A. Secreted enolase one (ENO1) was
used as a loading control (36).
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peutic target. Further studies to determine activin A
circulating levels in lean subjects and in obese patients
are required to better deﬁne the clinical role of activin A
and to validate activin A as a secreted biomarker.
Blocking activin A in adipose tissue of obese patients
could represent a new therapeutic avenue to modulate
the pool of adipose progenitors.
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FIG. 7. Expression of INHBA/activin A in adipose tissues and regulation by factors secreted by adipose tissue–derived macrophages. A:
Expression of INHBA in subcutaneous adipose tissue of lean (n  7) and morbidly obese (n  12) women. Expression was quantiﬁed by real-time
PCR and CD34
/CD31
, and results are shown by taking as 1 the signal obtained in adipose tissue of lean subjects. B: Effects of conditioned
medium from CD14
 adipose tissue macrophages on INHBA/activin A expression. INHBA expression in human preadipocytes treated for 10 days
with ATM-conditioned media (ATM-CM) compared with control medium (n  5). C: INHBA expression in CD34
/CD31
 adipose progenitors
treated for 24 h with ATM-conditioned media compared with control medium (n  7). Expression was quantiﬁed by real-time PCR. Values are
means  SEM. ATMs were isolated from women (mean age 39.33  4.37 years and mean BMI 26.21  2.54 kg/m
2). *Differ with P < 0.01. D:
Undifferentiated hMADS2 cells were treated with factors secreted by ATM isolated from three biopsies (ATM-CM 1–3) or with control media
(Ctr) for 24 h. The same volumes of conditioned media were maintained at 37°C in the absence of hMADS cells (ATM-CM alone). Culture media
were collected and analyzed for expression of activin A as described in Fig. 6B. Enolase 1 (ENO1) was used as a loading control. Enolase signals
shown on the left part of gel combine enolase levels present in the ATM-CM and levels secreted by hMADS cells. ATMs were isolated from women
(mean age 46.20  6.80 years and mean BMI 25.48  1.26 kg/m
2).
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